Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 17/20 | 0.77 |
| ▸ | ATM | Q13315 | 2/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059170 | 0.94 | PRKDC (0.73) | PRKDCATM | |
| SCHEMBL167830 | 0.93 | PRKDC (0.75) | PRKDCATM | |
| SCHEMBL166327 | 0.91 | PRKDC (0.72) | PRKDCATMKDR | |
| SCHEMBL174519 | 0.91 | PRKDC (0.67) | PRKDCATM | |
| SCHEMBL256573 | 0.91 | PRKDC (0.74) | PRKDCATMFGFR1FLT1FGFR2 | |
| SCHEMBL257304 | 0.90 | PRKDC (0.67) | PRKDCATMFGFR1FLT1FGFR2 | |
| SCHEMBL167978 | 0.88 | PRKDC (0.80) | PRKDCATMFGFR1FLT1FGFR2 | |
| SCHEMBL15064195 | 0.88 | PRKDC (0.66) | PRKDCATMFGFR1FLT1FGFR2 | |
| SCHEMBL168204 | 0.88 | PRKDC (0.68) | PRKDCATMFGFR1FLT1FGFR2 | |
| SCHEMBL15064244 | 0.88 | PRKDC (0.66) | PRKDCATMFGFR1FLT1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-03-24 | — | — | US | disclosed |
| US-11110108-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2018064092-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | TOP2B, TOP2A, TOP1 | PRKDC 211/4885ATM 144/4885FGFR1 1950/4885 |
| US-11110108-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | TOP2B, TOP2A, TOP1 | PRKDC 211/4885ATM 144/4885FGFR1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.